Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -40038.95% is 742% below its 5-year average of -4754.85%, near the low end of its 5-year range (-40038.95%–-69.83%).
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2025 (2025-09-30): -13989.47%.
EBITDA MARGIN
-40038.95%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
-6025.79%
EBITDA MARGIN AVG 5Y
-4754.85%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
-564.46%
CURRENT VS 5Y AVG
-742.07%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
aTyr Pharma, Inc.
Market Cap
$28.43M
EBITDA Margin
-40038.95%
TTM Avg
N/A
3Y Avg
-6025.79%
5Y Avg
-4754.85%
Market Cap
$27.31M
EBITDA Margin
-17954.61%
TTM Avg
-17954.61%
3Y Avg
-17954.61%
5Y Avg
-17954.61%
Market Cap
$30.65M
EBITDA Margin
-10097.04%
TTM Avg
-6618.17%
3Y Avg
-8743.58%
5Y Avg
-8072.84%
Market Cap
$31.36M
EBITDA Margin
-108.41%
TTM Avg
-31.49%
3Y Avg
5.24%
5Y Avg
21.14%
Market Cap
$25.48M
EBITDA Margin
-883.91%
TTM Avg
-2536.80%
3Y Avg
-2479.09%
5Y Avg
-2025.77%
Market Cap
$24.65M
EBITDA Margin
-701.04%
TTM Avg
-599.88%
3Y Avg
-518.61%
5Y Avg
-381.18%
Market Cap
$32.31M
EBITDA Margin
-29.82%
TTM Avg
-228.84%
3Y Avg
-176.67%
5Y Avg
-120.12%
Market Cap
$32.32M
EBITDA Margin
-2671.72%
TTM Avg
-3785.12%
3Y Avg
-14400.08%
5Y Avg
-14400.08%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| aTyr Pharma, Inc. (ATYR) | $28.43M | -40038.95% | N/A | -6025.79% | -4754.85% |
| GridAI Technologies Corp. (GRDX)vs › | $27.31M | -17954.61% | -17954.61% | -17954.61% | -17954.61% |
| CervoMed Inc. (CRVO)vs › | $30.65M | -10097.04% | -6618.17% | -8743.58% | -8072.84% |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | -108.41% | -31.49% | 5.24% | 21.14% |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.48M | -883.91% | -2536.80% | -2479.09% | -2025.77% |
| Kyntra Bio, Inc. (KYNB)vs › | $24.65M | -701.04% | -599.88% | -518.61% | -381.18% |
| EUDA Health Holdings Limited (EUDA)vs › | $32.31M | -29.82% | -228.84% | -176.67% | -120.12% |
| BeyondSpring Inc. (BYSI)vs › | $32.32M | -2671.72% | -3785.12% | -14400.08% | -14400.08% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | -710238.40% | -369696.29% | -185511.92% | -193923.76% |
Gross Margin
-717.4%
EBITDA Margin
-40038.9%
Operating Margin
-40856.3%
Net Margin
-32003.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-09-30 | -13989.47% |
| 2024-03-31 | -6751.49% |
| 2023-09-30 | -3292.35% |
| 2022-12-31 | -69.83% |
| 2020-12-31 | -228.64% |
| 2020-09-30 | -4197.30% |
| 2020-06-30 | -3151.32% |
| 2020-03-31 | 27.49% |
| 2019-12-31 | -3895.83% |
| 2019-09-30 | -2802.72% |
| 2019-06-30 | -5642.55% |
